"Wegovy Generics Flood the Market at One-Eighth the Price, Just 20,000 Won per Month"
Semaglutide Patent Expires in India
Over 50 Generic Brands Expected to Launch This Year
With the expiration of the patent for the main ingredient in the obesity treatment drug Wegovy, ultra-low-cost generic versions—priced at one-eighth the cost of Wegovy—have begun to flood the market in India, the world's largest producer of generic drugs. This development is drawing attention to the potential impact on the global obesity treatment market.
According to AFP, Bloomberg, and The New York Times on the 21st (local time), Indian pharmaceutical company Eris Lifesciences launched a generic injectable version of Wegovy under its diabetes treatment brand "Sunday" the previous day. The price for the generic drug is set at 1,290 rupees per month (approximately 20,700 won) for the lowest 2mg dose, which is about 12% of the cost of the original Wegovy.
Another pharmaceutical company, Dr. Reddy's Laboratories, also entered the competition on the same day by launching its own Wegovy generic called "Obeda." The company aims to release Obeda in Canada by May as well.
The patent for semaglutide, the main ingredient in Wegovy, expired in India as of the previous day. According to pharmaceutical market research firm Pharmarack, including these companies, around 42 pharmaceutical companies in India are expected to release more than 50 brands of Wegovy generics this year.
Indian pharmaceutical companies, which are globally known for their production of low-cost generics, are expected to offer Wegovy generics at least 50–60% cheaper than the original product. Industry sources predict that prices could drop even further as competition intensifies. Currently, the highest dose of Wegovy in the United States is priced at 349 dollars per month (approximately 520,000 won).
AFP reported that "the core patent for semaglutide is set to expire in 10 major countries worldwide, including China, Brazil, Canada, and South Africa, by the end of this year." As a result, the introduction of affordable generics is expected to trigger an explosion in demand in developing countries such as India, where the relatively high price has previously slowed the adoption of obesity treatments. There are over 800 million overweight or obese adults in India and China combined.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Nadeem Rais, an endocrinologist based in Mumbai, the economic hub of western India, told AFP, "Currently, 70 to 80 patients are receiving (obesity treatment) therapy," adding, "If generics become available and prices drop, the number of patients could easily increase to 200."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.